Understanding the Market | CanSinoBIO opened over 3% higher after earnings, with a net profit attributable to the parent company of 14.4401 million yuan in the first three quarters. The company will participate in the CPHI exhibition again
CanSinoBIO opened over 3% higher after earnings, and as of the time of publication, it rose 3.36% to HKD 44.96, with a transaction volume of HKD 998,100. In terms of news, on October 27, CanSinoBIO released its performance for the first three quarters, achieving an operating income of 693 million yuan for the nine months ending September 30, 2025, a year-on-year increase of 22.13%; the net profit attributable to shareholders of the listed company was 14.4401 million yuan, compared to a net loss of 222 million yuan in the same period last year. The basic earnings per share were 0.06 yuan. It is worth mentioning that according to CanSinoBIO's official WeChat account, from October 28 to 30, the world's largest professional exhibition in the pharmaceutical industry—the CPHI Europe 2025—will be held in Frankfurt, Germany. CanSinoBIO will showcase its rich product line developed in-house, highlighting its outstanding advantages and deep accumulation in key areas such as innovative pneumonia vaccines, meningitis vaccines, and combined DTP vaccines, and will initiate innovative cooperation and business expansion in the global vaccine CRDMO field
According to Zhitong Finance APP, CanSinoBIO (06185) opened over 3% higher after its earnings report, and as of the time of writing, it has risen 3.36% to HKD 44.96, with a trading volume of HKD 998,100.
In terms of news, on October 27, CanSinoBIO released its performance for the first three quarters, reporting an operating income of RMB 693 million for the nine months ending September 30, 2025, a year-on-year increase of 22.13%; the net profit attributable to shareholders of the listed company was RMB 14.44 million, compared to a net loss of RMB 222 million in the same period last year. The basic earnings per share were RMB 0.06.
It is worth mentioning that according to CanSinoBIO's official WeChat account, from October 28 to 30, the world's largest professional exhibition in the pharmaceutical industry—the CPHI Europe 2025—will be held in Frankfurt, Germany. CanSinoBIO will showcase its rich product line developed in-house, highlighting its outstanding advantages and deep accumulation in key areas such as innovative pneumonia vaccines, meningitis vaccines, and combined DTP vaccines, and will initiate innovative cooperation and business expansion in the global vaccine CRDMO field
